share_log

Baird:维持Crinetics Pharmaceuticals(CRNX.US)评级,由优于大市调整至优于大市评级, 目标价由52.00美元调整至62.00美元。

Baird: Maintaining the Crinetics Pharmaceuticals (CRNX.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $52.00 to $62.00.

Zhitong Finance ·  May 24 00:40
Baird: Maintaining the Crinetics Pharmaceuticals (CRNX.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $52.00 to $62.00.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment